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Abstract
Purpose Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET).
However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the
main therapeutic sequences in G1−G2 NET.
Methods A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in
NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and
grade of side effects and the rate of dose reduction/treatment discontinuation.
Results Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 gastro-
enteropancreatic, lung and unknown primary NET, unresectable or persistent/relapsing after surgery, treated with ≥2 sys-
temic treatments, were included. Four main therapeutic sequences were identified in 99 patients: (A) somatostatin analogs
(SSA) standard dose to SSA high dose (n= 36), (B) SSA to everolimus (n= 31), (C) SSA to chemotherapy (n= 17), (D)
SSA to peptide receptor radionuclide therapy (PRRT) (n= 15). Median PFS of the second-line treatment was not reached in
sequence A, 33 months in sequence B, 20 months in sequence C, 30 months in sequence D (p= 0.16). Both total number
and severity of side effects were significantly higher in sequences B and C than A and D (p= 0.04), as well as the rate of
dose reduction/discontinuation (p= 0.03).
Conclusions SSA followed by SSA high dose, everolimus, chemotherapy or PRRT represent the main therapeutic sequences
in G1−G2 NET. Median PFS was not significantly different between sequences. However, the sequences with SSA high
dose or PRRT seem to be better tolerated than sequences with everolimus or chemotherapy.
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Introduction
Neuroendocrine neoplasias are a heterogeneous group of
tumors that originate from different tissues and organs, with
more than half of the cases involving the digestive system
[1]. Their incidence has dramatically increased in the last 40
years, being now estimated to be about 7 per 100,000
persons [2]. Most cases arise from pancreas, intestine and
lung and are well-differentiated neuroendocrine tumors
(NET), grade 1 (G1) and grade 2 (G2), which are char-
acterized by indolent growth rate and long-time survival.
However, more than 50% of the cases present with regional
or distant metastases at the time of diagnosis [2]. Whereas
the treatment of choice of localized NET is surgical resec-
tion, a wide spectrum of therapeutic options is available for
patients with advanced, unresectable NET. The manage-
ment of patients with metastatic or regionally advanced G1
or G2 gastroenteropancreatic (GEP) and lung NET is based
on different therapeutic options such as somatostatin ana-
logs (SSA), molecular targeting therapies (everolimus and
sunitinib), chemotherapy and peptide receptor radionuclide
therapy (PRRT) [3–5]. These can be used alone or as a
multimodal approach. All these treatments can be con-
sidered in this setting according to guidelines [6–9]. How-
ever, a precise therapeutic algorithm defining the sequence
of treatments in patients with unresectable G1−G2 NET has
not yet been established.
In the present study, we aim to identify the most frequent
therapeutic sequences in patients with G1−G2 NET, as well
as to compare efficacy and toxicity between the identified
sequences.
Patients and methods
Study design
This is a retrospective observational study. Data have been
collected through an e-CRF and stored in a centralized
computer database ad hoc created and active since 2011 in
the context of the project “ELIOS” (Educational Learning
Investigational Observational Study). A first observational
study has been performed to evaluate the response to SSA
according to Ki67 index in patients with NET [10]. In
September 2016 the ELIOS group started a new observa-
tional study to evaluate and compare efficacy and toler-
ability of well-defined therapeutic sequences in patients
with GEP, lung and unknown primary site NET. The cur-
rent one is an Italian multicenter study where retrospective
data of patients in follow-up in one of the centers of the
ELIOS group from January 2005 to September 2017 were
included. For this project, eight centers were involved in the
ELIOS group, Federico II University of Naples, Cardarelli
Hospital, National Cancer Institute of Naples Fondazione G.
Pascale, Monaldi Hospital, University of Palermo, Istituto
Oncologico del Mediterraneo, IRCCS Casa Sollievo della
Sofferenza, Lecce Hospital.
Because no previous study explored the relationship
between therapeutic sequences with PFS in patients with
NET, it was not possible to define a relevant effect size and,
consequently, a priori power analysis to determine the
required sample size. Therefore, the sampling was based on
the retrospective revision of a multicentric NET database,
by taking into account those NET patients fulfilling the
inclusion criteria reported below and receiving the most
frequent therapeutic sequences among those used in the
clinical practice until now.
Inclusion criteria were: age ≥ 18 yrs, histopathologically
confirmed GEP, lung and unknown primary NET, well or
moderately differentiated (G1 or G2 according to WHO
2010 for GEP NET or typical and atypical lung carcinoids
according to WHO 2015 for thoracic NET) [11, 12],
metastatic or locally advanced disease at diagnosis or per-
sisting/relapsing after surgery, functioning or nonfunction-
ing, at least two types of antitumor treatments among SSA,
targeted therapy, chemotherapy, PRRT, administered
sequentially as first- and second-line therapy, first outpatient
visit in the NET Center between 1 January 2005 and 30
September 2016, ≥1 yr follow-up, adequate liver and renal
function.
The treatment sequences were established patient by
patient by the multidisciplinary NET team, based on local
availability and personal preferences. Treatment dis-
continuation occurred in patients with Response Evaluation
Criteria in Solid Tumors (RECIST) progression or in those
experiencing an unacceptable toxicity (grade 3 or 4). SSA at
standard doses schedule, including octreotide LAR 30 mg
or lanreotide autogel 120 mg every 28 days, and high doses
schedule, including octreotide LAR 30 mg and lanreotide
autogel 120 mg every 14−21 days, were considered as
separate treatments in the analysis of sequences, according
to the last ENETS guidelines where a higher than standard
dose of SSA can be considered in NET patients with radi-
ological progression [6]. Supportive concomitant therapies
and external palliative radiotherapy were allowed.
Exclusion criteria were: age < 18 yrs, pregnant or breast-
feeding patients, NET G3, poorly differentiated neu-
roendocrine carcinoma and mixed tumors, NET of primary
sites other than GEP and lung.
The primary endpoints of the study were in G1−G2
unresectable treatment-naive NET: (a) to identify the most
frequent therapeutic sequences (first- and second-line
treatment) among those used in the clinical practice until
now; (b) to compare the median progression-free survival
(PFS) after first- and second-line treatment, the rate of total
and serious adverse events as well as the rate of treatment
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discontinuation/dose reduction between the identified ther-
apeutic sequences.
Patient characteristics
A total number of 1182 patients has been included in the
ELIOS database at September 2017, involving subjects
followed-up in one of the NET centers of the ELIOS group
between January 2005 and September 2016. Of them, 420
patients with diagnosis of G1−G2 NET of pancreatic,
gastrointestinal, lung or unknown primary were examined
as potentially eligible for the study. Finally, 131 of 420
patients fulfilled all the inclusion criteria and were analyzed
for the therapeutic sequences. A central pathology review
was performed for all tumors included in the ELIOS data-
base, according to the last WHO classifications of GEP and
lung NET [11, 12].
Efficacy and safety assessment
Efficacy was assessed through the evaluation of median
PFS after both first- and second-line treatment, defined as
the time from the beginning of each line of treatment until
tumor progression, treatment discontinuation, or until the
last follow-up evaluation or death. Tumor progression was
evaluated according to the RECIST v1.1. The radiologic
assessment of tumor lesions was performed by contrast
enhanced computerized tomography (CT) or magnetic
resonance imaging, at baseline and every 3−6 months
during the follow-up period. Toxicity was evaluated
through the record of adverse events according to Common
Terminology Criteria for Adverse Events (CTCAE) v4.0.
Also the rate of dose modification and treatment dis-
continuation after each sequence of treatment were
considered.
Statistical analysis
Data were expressed as mean (±standard deviation) for
continuous variables and as frequencies and percentages
(%) for categorical data. To determine differences among
sequences in terms of demographics and clinico-
pathological characteristics, ANOVA, χ2 tests or Fisher
exact were performed as appropriate. Kaplan−Meier ana-
lysis and log-rank test were used to compare PFS among
sequences. Cox regression analyses were performed to
provide hazard ratios (HRs). Finally, comparisons of treat-
ment toxicity between the four sequences were performed
using the χ2 test or Fisher exact test as appropriate. The
statistical software R, version 3.2.5 [13] was used for all
statistical analyses. The p value < 0.05 was taken as the
level of significance.
Results
Patient parameters
Among the 131 patients fulfilling the inclusion criteria of
the study, four most recurrent sequences were identified:
(A) SSA standard dose to SSA high dose, (B) SSA to
everolimus; (C) SSA to chemotherapy, (D) SSA to PRRT.
SSA therapy represented the first line in all sequences.
These four sequences involved 99 of 131 patients (75.6%)
who formed the final dataset for the statistical analysis, as
follows: sequence A 36 patients, sequence B 31 patients,
sequence C 17 patients, sequence D 15 patients (Table 1).
The remaining 32 patients, treated with different therapeutic
sequences, were excluded (Table 2).
The final group of 99 patients included 57.6% males
and 42.4% females, age at diagnosis 55.9 years on
average (Table 3). According to primary site, there were
45.4% gastrointestinal NET (GI-NET), 32.3% pancreatic
NET (P-NET) and 16.2% lung NET (L-NET), while 6.1%
of tumors had unknown primary (UP). GI-NET were G1
in 48.9% and G2 in 51.1%. P-NET were G1 in 53.1% and
G2 in 46.9%. Unknown primary tumors were G1 in
16.7% and G2 in 83.3%. Bronchial carcinoids were
typical in 43.7% and atypical in 56.3%. All typical
Table 1 Main therapeutic sequences identified in 99 patients with NET
undergone ≥2 lines of treatment
Number of patients
(A) SSA standard dose–SSA high dose 36
(B) SSA–everolimus 31
(C) SSA–chemotherapy 17
(D) SSA–PRRT 15
Total 99
NET neuroendocrine tumors, SSA somatostatin analogs, PRRT peptide
receptor radionuclide therapy
Table 2 Less recurrent therapeutic sequences, identified in other 32
NET patients, not considered for the statistical analysis
Number of patients
Chemotherapy–SSA 10
SSA–other targeted therapies 5
SSA lower dose–SSA full standard dose 4
Chemotherapy (first line)–chemotherapy (second line) 4
Everolimus–SSA 3
Chemotherapy–everolimus 4
PRRT–SSA 2
Total 32
NET neuroendocrine tumors, SSA somatostatin analogs, PRRT peptide
receptor radionuclide therapy
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carcinoids were G1 and all atypical carcinoids were G2.
As a whole 47.5% of the tumors were G1 and 52.5% were
G2. Primary tumor was resected in 47.5%. Disease
status before the first-line treatment was available in 80
patients, which were progressive in 56.2%, stable in
43.8% (Table 3).
Baseline characteristics such as age, sex, tumor stage,
functional status, resection of primary tumor and disease
status at baseline were similar between sequences, while
tumor site and grading varied but not significantly (Table 4).
Chemotherapy included capecitabine in nine patients,
temozolomide in six patients and the combination in two
patients. Concomitant supportive therapies for symptomatic
bone metastases were performed in ten patients, equally
distributed according to sequences (three in sequence A,
four in B, two in C, one in D). Five of them were treated
with external radiotherapy.
Efficacy
Every sequence had two lines of treatment and PFS was
calculated for each line. As expected, there was no statis-
tical difference in PFS of the first line between the four
sequences, which consist in SSA in all of them (p= 0.77).
Median PFS was 16.5 months for sequence A, 17 months
for B, 20 months for C and 20 months for D (Fig. 1a).
PFS was not significantly different between sequences
(p= 0.16) for the second line of treatment as well (Fig. 1b).
Median PFS was not reached in sequence A, whereas it was
33 months for B, 20 months for C and 30 months for D.
HRs for PFS, for the two lines of treatment, are reported in
Table 5.
When analyzing the second-line median PFS with
respect to primary site, no significant difference was found
(p= 0.89), while median PFS was longer in G1 than G2
NET (40 vs. 27 months, p= 0.04), as well as in stable
tumors rather than in those progressive at baseline (57 vs.
24 months, p= 0.02).
An objective response rate was observed in 11 patients
(11.1%), including 4 patients in sequence A (11.1%), 3
patients in sequence B (9.7%), 3 patients in sequence C
(17.6%) and 1 patient in sequence D (6.7%), without sig-
nificant difference (p= 0.81).
Toxicity
In 45 patients out of 99 (45%), no adverse events were
recorded. The remaining 55% of cases, on the other hand,
presented most frequently grade 1−3 adverse events. The
different sequences were significantly associated with
adverse events (p= 0.04). Table 6 shows the distribution of
adverse events over the four sequences. A higher level of
toxicity was found for sequence B (67.7%) and C (70.6%)
than sequence A (44.4%) and D (33.3%) (p= 0.043). As for
the severity of side effects, grade 3 or 4 adverse events were
5.6% in sequence A, 25.8% in sequence B, 29.4% in
sequence C and 6.7% in sequence D (p= 0.030). Side
effects lead to discontinuation of the treatment or reduction
of the administered doses in significantly different rates
over the four different sequences (p= 0.028). The rates of
discontinuation/dose reduction were 2.8% for those treated
with sequence A and 6.7% for those treated with sequence
D. The other two sequences, instead, showed higher rates of
discontinuation/dose reduction (16.1% for sequence B and
29.4% for C).
Discussion
The spectrum of treatments now available for NET
includes SSA such as octreotide and lanreotide, targeted
therapies such as everolimus and sunitinib, chemotherapy
and finally PRRT with radiolabelled SSA [14–20].
Although no randomized trial has been published until
now to study the higher than standard dose of SSA in
NET, except the Netter study where octreotide LAR
60 mg per month represents the control arm, this schedule
is also an option for progressive G1-G2 NET, as reported
in the ENETS guidelines [6].
Table 3 Baseline characteristics of the 99 NET patients included in the
statistical analysis
Age (mean ± SD, range) 55.9 ± 13.3 yrs, 19−80
Number of patients
Sex
Male/female 57/42
Primary site
Pancreas 32
Gastrointestinal 45
Small intestine 26
Stomach 6
Duodenum 6
Colon/rectum 7
Lung 16
Unknown primary 6
Tumor grade
All NET (G1/G2) 47/52
Pancreatic NET (G1/G2) 17/15
Gastrointestinal NET
(G1/G2)
22/23
Lung NET (G1/G2) 7/9
Unknown primary (G1/G2) 1/5
Primary tumor resected 47
Disease status
Progression 45
Stability 35
Unknown 19
Data are reported as number of patients or mean (±standard deviations
and range) as appropriate
NET neuroendocrine tumors, G grade
Endocrine
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NET guidelines have been progressively improved. The
last ENETS, NANETS, NCCN, ESMO guidelines all try to
provide NET treatment algorithms based on stage and grade
of NET rather than on primary site [6–9]. This is a first
attempt to place the biology of the tumor at the center of
decision-making and therapeutic choice, while waiting for
an algorithm based on the genetic alterations of NET as for
other tumor models. All the biological characteristics of
NET available nowadays, such as neuroendocrine differ-
entiation, tumor grade, somatostatin receptor status, func-
tional status, help select or exclude certain therapies instead
of others [21]. However, a therapeutic strategy, i.e. the
definition of the sequence of treatments to be used over
time, has never been established.
In the vast group of patients with GEP and lung, G1 and
G2, loco-regionally advanced or metastatic, surgically
unresectable NET, the clinical trials performed until now
only concern efficacy and toxicity of a single line of treat-
ment with SSA, everolimus, sunitinib, chemotherapy,
Table 4 Primary site and tumor
grading according to sequences
in the 99 NET patients evaluated
Sequence
A B C D Total p value
Primary tumor
Pancreas 9 (25%) 15 (48.4%) 5 (29.4%) 3 (20%) 32 (32.3%) 0.169
GI 21 (58.3%) 8 (25.8%) 9 (52.9%) 7 (46.7%) 7 (46.7%)
Lung 3 (8.3%) 6 (19.4%) 3 (17.6%) 4 (26.7%) 4 (26.7%)
Unknown 3 (8.3%) 2 (6.5%) 0 (0%) 1 (6.7%) 1 (6.7%)
Tumor grade
G1 22 (61.1%) 10 (32.3%) 9 (52.9%) 6 (40%) 47 (47.5%) 0.109
G2 14 (38.9%) 21 (67.7%) 8 (47.1%) 9 (60%) 52 (52.5%)
Data are reported as number of patients (%)
NET neuroendocrine tumors, GI gastrointestinal
Fig. 1 Kaplan−Meier analysis: a Median PFS of the first-line treat-
ment was 16.5 months for sequence A (SSA standard dose to SSA
high dose), 17 months for B (SSA to everolimus), 20 months for C
(SSA to chemotherapy) and 20 months for D (SSA to PRRT), without
statistical difference in PFS between the four sequences (p= 0.77). b
Median PFS of the second-line treatment was not reached in sequence
A, whereas it was 33 months for B, 20 months for C and 30 months for
D, without statistical difference in PFS between sequences (p= 0.16).
PFS progression-free survival, SSA somatostatin analogs, PRRT
peptide receptor radionuclide therapy
Table 5 HRs estimated using Cox proportional hazard regression
analyses for the associations between sequences and PFS, for the two
lines of treatment
First line Second line
HR (95% CI) p value HR (95% CI) p value
Sequence
A 1.02 (0.55−1.87) 0.952 0.58 (0.21−1.61) 0.300
B 0.79 (0.42−1.49) 0.466 1.40 (0.58−3.37) 0.449
C 0.95 (0.48−1.91) 0.897 1.45 (0.50−4.19) 0.493
Sequence D as reference category
HR hazard ratio, PFS progression-free survival, CI confidence interval
Endocrine
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PRRT, while the effects of a whole sequence are not known.
This would be relevant to optimize the efficacy of NET
therapy and to increase the patient tolerability to each drug
administered as well as to the whole sequence of treatments.
On the other hand, a high tolerability is also related to low
rates of drug interruption and discontinuation and conse-
quently is likely to induce a better effectiveness.
In this setting, whereas SSA are widely accepted as first-
line treatment, because of their positive benefit/risk ratio, no
data are available to establish the best choice as second-line
treatment [22, 23]. This is the first study with the purpose of
trying to answer this unmet need, by analyzing and com-
paring the main therapeutic sequences in a large retro-
spective series of G1−G2 NET. Four main therapeutic
sequences were identified. As expected, all started with SSA
as first-line treatment and continued with more aggressive
approaches after progression. Some other sequences starting
with chemotherapy, targeted therapy or PRRT were less
represented in this population.
The first-line treatment with SSA appeared to be as
homogeneously efficacious as expected, with a median PFS
from 16.5 to 20 months between sequences. This result is in
the middle between those of Promid and Clarinet trials,
where the experimental arm had a time to progression of
14.3 in the former and a median PFS not reached in the
latter [14, 15]. The difference of median PFS could be in
part explained by baseline tumor progression rate, which
was 56% in the current study, while only 4% in the Clarinet
and not indicated, but likely much higher, in Promid study.
In the Clarinet extension study, the subgroup of patients
previously progressing on placebo had a median PFS of
19 months after therapy with lanreotide [24]. Interestingly,
also the comparison between the second-line treatments of
the four sequences revealed no significant difference in
median PFS. The median PFS was not reached in sequence
A containing SSA high dose, while it was 33 months in
sequence B containing everolimus, 20 months in sequence
C containing chemotherapy, 30 months in sequence D
involving PRRT.
One of the strengths of this project is the study popula-
tion that included a large number of G1−G2 patients,
selected on the basis of well-defined inclusion and exclu-
sion criteria. All patients were treatment naive, thus
avoiding confounding factors due to previous treatments
which can impact on both efficacy and cumulative toxicity.
Among the weaknesses of the study, it has to be considered
the retrospective design. However, because the four sub-
groups of patients were homogenous with respect to
demographics and clinico-pathological characteristics, only
univariate analysis was performed. Beyond this, there are no
comparable reports available in literature and this represents
a pilot study on therapeutic sequences in NET, useful to
open the way for further prospective trials. Indeed, a highly
informative phase 3 trial, the SEQTOR trial (ClinicalTrials.
gov Identifier: NCT02246127), whose aim is to compare
prospectively in pancreatic NET two different therapeutic
sequences, everolimus followed by streptozocin/fluorouracil
vs. streptozocin/fluorouracil followed by everolimus, is still
ongoing.
Very few studies evaluated retrospectively efficacy and
tolerability of antitumor agents in NET patients according to
previous treatments. In all cases, study design was retro-
spective. In particular, everolimus resulted to induce similar
PFS rates according to previous treatments, but to be poorly
tolerated in NET patients previously treated with PRRT or
chemotherapy and even more in those treated with the
combination [25, 26]. Another study has retrospectively
compared the sequence everolimus to sunitinib vs. the
sequence sunitinib to everolimus in a series of 31 pro-
gressive metastatic G1−G2 pancreatic NET [27]. PFS was
not significantly different between sequences, while toxicity
was reported higher with sunitinib compared to everolimus
both in terms of frequency of serious adverse events and
rate of treatment discontinuation. However, none of these
Table 6 Distribution of adverse
events, severity of adverse
effects and discontinuation of
the treatment or reduction of the
administered doses in the 99
NET patients evaluated
Sequence
A B C D Total p value
Adverse events
0 20 (55.6%) 10 (32.3%) 5 (29.4%) 10 (66.7%) 45 (45.5%) 0.043
1 16 (44.4%) 21 (67.7%) 12 (70.6%) 5 (33.3%) 54 (54.5%)
SAE grade 3/4
0 34 (94.4%) 23 (74.2%) 12 (70.6%) 14 (93.3%) 83 (83.8%) 0.030
1 2 (5.6%) 8 (25.8%) 5 (29.4%) 1 (6.7%) 16 (16.2%)
Discontinuation/reduction
0 35 (97.2%) 26 (83.9%) 12 (70.6%) 14 (93.3%) 87 (87.9%) 0.028
1 1 (2.8%) 5 (16.1%) 5 (29.4%) 1 (6.7%) 12 (12.1%)
Data are reported as number of patients (%)
NET neuroendocrine tumors, SAE serious adverse events
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parameters reached the statistical significance. Interestingly,
a tendency to a higher frequency of serious adverse events
in sequential than in first-line treatments was observed both
for everolimus and sunitinib, but also in this case there was
no statistical significance [27]. As for Angelousi and co-
workers, in the present study PFS was similar between
sequences even if the comparison was between different
classes of drugs such as SSA, everolimus, chemotherapy
and PRRT. This finding is not surprising if we consider that
G1−G2 NET are slowly growing tumors that can be sta-
bilized as best response to each one of these treatments. The
median PFS in this study was higher as compared to that
from Angelousi but also to some phase-3 trials with SSA
high dose, PRRT or everolimus [16, 18, 27]. One possible
explanation is the longer follow-up time in the former
compared to that reported in most of the other studies.
Conversely, the Clarinet extension study, characterized by a
long-time follow-up, reported a median PFS > 30 months in
patients treated with lanreotide autogel 120 mg every
28 days [20, 24]. Another point is that most of the previous
studies enrolled patients who had been previously heavily
treated [16–18, 27]. In particular, in the retrospective study
comparing everolimus and sunitinib, other treatments such
as SSA, PRRT, chemotherapy and liver-directed therapy
had been used in 71%, 58%, 39% and 23% of cases,
respectively [27]. Radiant-2, -3 and -4 trials, comparing
everolimus and placebo, enrolled patients previously treated
with SSA (50−80%), chemotherapy (25−50%), radiation
therapy (21−22%) [16, 17]. In Netter trial, comparing
PRRT and SSA high dose in patients who progressed after
SSA standard dose, almost half of the patients had received
previous systemic treatments before SSA [18]. Anyway, the
retrospective data of the current study need to be pro-
spectively confirmed.
Whether efficacy does not allow discrimination between
the four sequences, this is not the case with regard to
toxicity. The better tolerability of sequences with SSA and
PRRT and without targeted therapy and chemotherapy is in
line with a recent national survey, where chemotherapy,
everolimus and sunitinib had an odd ratio of poor perceived
tolerance which was respectively 1.7, 3.4 and 5.9 compared
to SSA [28]. Furthermore, for everolimus and sunitinib the
commonest cause of discontinuation was toxicity rather
than progression [28]. This is a crucial point that suggests to
favor sequences with SSA as first treatment and SSA high
doses or PPRT as sequential treatment. More aggressive
options like chemotherapy and targeted therapy should be
then considered in case of further progression.
In conclusion, this is the first study comparing different
therapeutic sequences in patients with G1−G2 NET not
previously treated. A similar efficacy is suggested for
sequences starting with SSA and continuing with SSA high
dose, everolimus, chemotherapy or PRRT, while those with
high dose or radio-labeled SSA seem to be better tolerated.
These findings represent a step forward in NET therapy by
suggesting a therapeutic algorithm in G1−G2 GEP and lung
NET, but require to be confirmed in prospective trials
involving large study populations.
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